Skip to main content
  1. Home
  2. Emerging Tech
  3. News

For 100,000 bucks, this South Korean biotech firm will clone your dog

Add as a preferred source on Google

South Korea’s Sooam Biotech opened its doors to its cloning laboratory in 2006 and made headlines a year later with Missy, the world’s first cloning of a companion dog. In the intervening years, the company has ushered in a brave, new world where a dog can live long beyond his death as long as you save some of the canine’s skin cells and have an extra $100,000 to burn.

The technique to clone a dog is surprisingly simple from a theoretical standpoint. DNA from the dog to be cloned is collected from the skin or other live cells. While the cloned DNA is being processed, a donor egg is collected from a female dog and emptied of its DNA by removing the nucleus. The cloned dog’s DNA is injected into the empty egg and fused with the embryonic contents. This embryo is then implanted into a surrogate female dog who carries and delivers the cloned puppy.

Recommended Videos

Sooam Biotech has been honing its technique for cloning dogs, with one of their latest cloning attempts producing not one, but three cloned puppies. One of the puppies perished from distemper shortly after birth. Two of the other puppies survived, providing happy owners Phillip and Paula Dupont with Ken and Henry, two almost perfect replicas of their cherished dog Melvin.

Cloning may be producing happy pet owners worldwide, but the technique is criticized by animal advocates and medical ethicists alike. Animal supporters point to the high price tag of cloning and question whether that money would be better spent supporting abandoned dogs in shelters, instead of producing designer dogs. Bioethicists also question the surgeries and other medical procedures inflicted on the dogs involved in the cloning process. The cloning process has a high failure rate with multiple attempts often needed to produce a single clone. These detractors, though, don’t deter per owners who want preserve their loving companions. The Duponts already are considering another clone of their beloved dog Melvin, this time the pup will be given to their grandson.

Kelly Hodgkins
Kelly's been writing online for ten years, working at Gizmodo, TUAW, and BGR among others. Living near the White Mountains of…
Students who use AI every day may be falling behind, while moderate users pull ahead
New global testing data suggests more AI in the classroom isn't automatically better.
Logo, Text

I assumed more AI access might help students learn faster. However, a new OECD study dispels that misconception for me and everyone else who gave their children a paid version of AI chatbots, thinking it would help them through their educational journey. 

According to PISA 2025 data from 760,000 students in 91 countries, students who use AI daily score meaningfully worse on standardized tests than their peers. The full picture is more complicated than a simple ban would fix.

Read more
XPENG just put its humanoid robot on the production line, and it walked itself out
IRON clocks in for its first shift
XPENG Iron

XPENG’s humanoid robot has officially joined the workforce, and it even got an employee badge. The Chinese automaker announced on September 8 that its next-generation IRON had completed assembly and autonomously walked off its newly commissioned humanoid robot production line in Guangzhou.

CEO He Xiaopeng then pinned a staff badge onto the robot, symbolically welcoming it to the XPENG team. It is a charming little ceremony for a machine that the company hopes will eventually become a regular part of everyday life. XPENG is moving IRON beyond R&D prototypes toward production-line manufacturing, applying the quality-control systems and manufacturing experience it has developed through its electric vehicle business.

Read more
An AI-designed drug might help slow aging, but we’re not there yet
The results hint at a possible anti-aging effect, but there’s still a long way to go before we know what it means.
medical test tubes

Rentosertib, a drug Insilico Medicine designed almost entirely using AI, was created to treat idiopathic pulmonary fibrosis, a disease that scars and stiffens the lungs over time. But fighting lung disease was only half the plan from the start.

According to a new study published in Nature Biotechnology, the drug's target was chosen specifically because it overlaps heavily with the biology of aging, and the whole trial was designed to test whether treating the lungs could also mean turning back the body's biological clock.

Read more